Jacobs Levy Equity Management Inc. Sells 95,157 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)

Jacobs Levy Equity Management Inc. cut its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 18.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 414,120 shares of the medical instruments supplier's stock after selling 95,157 shares during the quarter. Jacobs Levy Equity Management Inc. owned 1.02% of AngioDynamics worth $3,222,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ANGO. Quarry LP grew its holdings in shares of AngioDynamics by 75.1% in the 2nd quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier's stock valued at $37,000 after acquiring an additional 2,594 shares in the last quarter. CWM LLC grew its stake in AngioDynamics by 981.3% in the 3rd quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier's stock valued at $76,000 after buying an additional 8,832 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new stake in AngioDynamics during the 3rd quarter worth approximately $86,000. SG Americas Securities LLC bought a new stake in shares of AngioDynamics in the third quarter valued at about $103,000. Finally, Mackenzie Financial Corp acquired a new position in shares of AngioDynamics during the 2nd quarter worth approximately $80,000. Institutional investors and hedge funds own 89.43% of the company's stock.

Insider Buying and Selling at AngioDynamics

In other news, CEO James C. Clemmer acquired 20,000 shares of the company's stock in a transaction that occurred on Monday, October 7th. The shares were acquired at an average price of $6.03 per share, for a total transaction of $120,600.00. Following the completion of the purchase, the chief executive officer now owns 681,582 shares in the company, valued at approximately $4,109,939.46. This trade represents a 3.02 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders purchased 22,568 shares of company stock worth $135,847. Insiders own 5.40% of the company's stock.

AngioDynamics Price Performance

Shares of AngioDynamics stock traded down $0.10 during midday trading on Friday, reaching $7.00. The company had a trading volume of 152,493 shares, compared to its average volume of 342,550. AngioDynamics, Inc. has a fifty-two week low of $5.26 and a fifty-two week high of $8.25. The stock has a fifty day moving average price of $6.84 and a 200 day moving average price of $6.85.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.04. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The business had revenue of $67.50 million during the quarter, compared to analysts' expectations of $67.93 million. During the same quarter last year, the firm posted ($0.12) earnings per share. The firm's revenue was down 14.2% on a year-over-year basis. As a group, research analysts expect that AngioDynamics, Inc. will post -0.41 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on ANGO shares. Canaccord Genuity Group dropped their price objective on AngioDynamics from $13.00 to $12.00 and set a "buy" rating for the company in a report on Friday, October 4th. HC Wainwright reiterated a "buy" rating and set a $14.00 price objective on shares of AngioDynamics in a research report on Friday, October 4th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.